Global Hepatitis C Drugs Market, by Drug Type (Interferon Based Therapies, NS5A Inhibitors, NS5B Inhibitors, and Protease Inhibitors), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 7,376.6 million in 2019 and is expected to exhibit a CAGR of 4.0% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.
Hepatitis C is a major liver disease, and it has become a global burden. Moreover, key players are focused on developing new drugs for the treatment of hepatitis C. Increasing launches of new drugs is expected to drive the hepatitis C drugs market growth. For instance, in 2019, The AbbVie Inc. company received the U.S. Food and Drug Administration approval for Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children of age group of 12 to 17.
Moreover, in 2018, Nacto Pharma ltd launched a drug with brand name as Hepcinat Plus for the treatment of hepatitis C disease. This drug is generic form and fixed combination of Sofosbuvir-Declatasvir tablet. The company launched this drug at a retail price of US$ 246.1 for 28 tablets.
Furthermore, in 2018, Gilead Sciences Company launched generic versions of Harvoni and Epclusa, which was valued at US$ 24,000 for full course of therapy. The launch of these drugs helped to resolve the issue related to high cost of branded drugs, which is around US$ 100,000 for full course of therapy.
Browse 26 Market Data Tables and 27 Figures spread through 151 Pages and in-depth TOC on "Global Hepatitis C Drugs Market, by Drug Type (Interferon Based Therapies, NS5A Inhibitors, NS5B Inhibitors, and Protease Inhibitors), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"
To know the latest trends and insights related to global Hepatitis C Drugs market, click the link below:
Moreover, in 2016, Organisation for Economic Co-operation and Development performed an economic analysis in Australia used a mathematical model, which was based on the WHO strategy’s targets. On the basis of the results of this analysis, in March 2016, the Australian Pharmaceutical Benefits scheme listed a number of DAAs (Direct-acting antivirals) for the treatment of hepatitis C, wherein it covers majority of the drug costs. As a result of this scheme, from March to September 2016, it was estimated that 25,900 number of people underwent treatment, which represents 11% of people with HCV infection.
Key Takeaways of the Global Hepatitis C Drugs Market: